Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
Journal of Virology|April 26, 2023
Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV NeutralizationMallika Sastry, Anita Changela, Jason Gorman, et al.
Science Immunology|April 21, 2019
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccineKenta Matsuda, Jinghe Huang, Tongqing Zhou, et al.
Cell Reports|July 12, 2023
HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptideShuishu Wang, Flavio Matassoli, Baoshan Zhang, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Nature Medicine|March 20, 2018
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasiteNeville K Kisalu, Azza H Idris, Connor Weidle, et al.
JCI Insight|November 25, 2025
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Nature Medicine|December 16, 2018
Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasiteNeville K Kisalu, Azza H Idris, Connor Weidle, et al.
The New England Journal of Medicine|September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsEvan J Anderson, Nadine G Rouphael, Alicia T Widge, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
Pageof 18